Here is the design of a clinical trial:

Official Title: Cerebral Microembolism in the Critically Ill With Acute Kidney Injury: A Prospective Multi-Center Randomized Controlled Trial Comparing Continuous With Intermittent Renal Replacement Therapy.

Included conditions:
- Cerebral Embolism

Study Armgroups:
- {'label': 'CRRT group', 'type': 'ACTIVE_COMPARATOR', 'description': 'the CRRT group receives continuous renal replacement therapy for acute kidney injury', 'interventionNames': ['Device: Renal replacement therapy']}
- {'label': 'IRRT group', 'type': 'ACTIVE_COMPARATOR', 'description': 'the IRRT group receives intermittent renal replacement therapy after termination of CRRT.', 'interventionNames': ['Device: Renal replacement therapy']}

Interventions:
- {'type': 'DEVICE', 'name': 'Renal replacement therapy', 'description': 'Patients receive renal replacement therapy according to institutional standards', 'armGroupLabels': ['CRRT group', 'IRRT group'], 'otherNames': ['Hemodialysis']}

Primary Outcomes:
- {'measure': 'Cerebral Microembolic Load detected by Transcranial Doppler Ultrasound', 'timeFrame': 'During hemodialysis therapy'}

Please estimate the sample size based on the assumption: 
Desired power of 0.8, significance level (alpha) of 0.05, and a dropout rate of 15%.
Sample size calculation
        Based on our preliminary study, [19] we expect a true difference in the mean high-intensity transient signals (HITS) value of 700 and a standard deviation of 950 HITS between the two groups of interest. With a desired power of 0.8 and an alpha of 0.05, the number of required patients is 58 (29/group). Taking into consideration a dropout rate of 15%, we plan to include a total number of patients of 66.